Literature DB >> 23817135

GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy.

Charles W Heilig1, Dilip K Deb, Afu Abdul, Hasan Riaz, Leighton R James, Jamal Salameh, N Stanley Nahman.   

Abstract

Diabetic glomerulosclerosis is characterized by accumulation of extracellular matrix proteins, mesangial expansion, and tubulointerstitial fibrosis. Hyperglycemia accelerates development of the disease, a direct result of increased intracellular glucose availability. The facilitative glucose transporter GLUT1 mediates mesangial cell glucose flux which leads to activation of signaling cascades favoring glomerulosclerosis, including pathways mediated by angiotensin II (Ang II), transforming growth factor β (TGF-β), connective tissue growth factor (CTGF), and vascular endothelial growth factor (VEGF). Ang II has both hemodynamic and metabolic effects directly inducing GLUT1 and/or matrix protein synthesis through diacyl glycerol (DAG) or protein kinase C (PKC) induction, mesangial cell stretch, and/or through transactivation of the epidermal growth factor receptor, the platelet-derived growth factor receptor, and the insulin-like growth factor-1 receptor, all of which may stimulate GLUT1 synthesis via an ERK-mediated pathway. Conversely, inhibition of Ang II effects suppresses GLUT1 and cellular glucose uptake. GLUT1-mediated glucose flux leads to metabolism of glucose via glycolysis, with induction of DAG, PKC, TGF-β1, CTGF and VEGF. VEGF in turn triggers both GLUT1 and matrix synthesis. New roles for GLUT1-mTOR and GLUT1-mechano-growth factor interactions in diabetic glomerulosclerosis have also recently been suggested. Recent mouse models confirmed roles for GLUT1 in vivo in stimulating glomerular growth factor expression, growth factor receptors and development of glomerulosclerosis. GLUT1 may therefore act in concert with cytokines and growth factors to induce diabetic glomerulosclerosis. Further clarification of the pathways involved may prove useful for the therapy of diabetic nephropathy. New directions for investigation are discussed.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817135     DOI: 10.1159/000351989

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  24 in total

1.  Different localization and expression of protein kinase C-beta in kidney cortex of diabetic nephropathy mice and its role in telmisartan treatment.

Authors:  Jianqing Wang; Fu Qin; Anguo Deng; Lijun Yao
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

Review 2.  Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options.

Authors:  Ahmed H Abdelhafiz
Journal:  Drugs Aging       Date:  2020-08       Impact factor: 3.923

3.  Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways.

Authors:  Mahefatiana Andrianifahanana; Danielle M Hernandez; Xueqian Yin; Jeong-Han Kang; Mi-Yeon Jung; Youli Wang; Eunhee S Yi; Anja C Roden; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2016-08-01       Impact factor: 5.191

Review 4.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

Review 5.  Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Authors:  Richard Van Krieken; Joan C Krepinsky
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

Review 6.  Prevalence and Management of Diabetic Nephropathy in Western Countries.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Dis (Basel)       Date:  2015-05-01

Review 7.  Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy.

Authors:  C Hu; L Sun; L Xiao; Y Han; X Fu; X Xiong; X Xu; Y Liu; S Yang; F Liu; Y S Kanwar
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

8.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.

Authors:  Ivan G Gomez; Deidre A MacKenna; Bryce G Johnson; Vivek Kaimal; Allie M Roach; Shuyu Ren; Naoki Nakagawa; Cuiyan Xin; Rick Newitt; Shweta Pandya; Tai-He Xia; Xueqing Liu; Dorin-Bogdan Borza; Monica Grafals; Stuart J Shankland; Jonathan Himmelfarb; Didier Portilla; Shiguang Liu; B Nelson Chau; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

9.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Authors:  Naoki Nakagawa; Luke Barron; Ivan G Gomez; Bryce G Johnson; Allie M Roach; Sei Kameoka; Richard M Jack; Mark L Lupher; Sina A Gharib; Jeremy S Duffield
Journal:  JCI Insight       Date:  2016-12-08

Review 10.  The tubular hypothesis of nephron filtration and diabetic kidney disease.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Nat Rev Nephrol       Date:  2020-03-09       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.